DIRS.INFO The most relevant business & tech news

☆ Google, Microsoft ChatGPT Clones Will Destroy Internet Search
▼ + stars: | 2023-02-09 | by ( Adam Rogers | ) www.businessinsider.com time to read: +13 min

The other kind of search — "exploratory search" — is the hard one. That's where you don't know what you don't know. When you're scrolling through the links in a Google search, looking for "esoteric shit," as one search expert calls it, you see some pages that just look dodgy, maybe in ways you can't even totally articulate. But search chatbots can fake all that. Google's search pages already aren't fully trustworthy — they overindex YouTube video results, for example, because YouTube is a subsidiary of Google.

☆ These innovation stocks owned by Cathie Wood have double-digit upside, according to analysts
▼ + stars: | 2023-02-06 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Cathie Wood just scored her best month ever as her innovation stocks staged a big comeback, and some of her darlings still have double-digit upside ahead, according to Wall Street analysts. Wood's flagship Ark Innovation ETF (ARKK) jumped 27.8% in January alone, notching its strongest month since its inception in 2014 . We looked at companies with at least five analysts covering them, and these names below all have more than 10% upside in the next 12 months, according to FactSet. Wall Street analysts are most bullish on Ginkgo Bioworks , seeing the stock rally more than 140% in the next 12 months. Other biotech names in the space that analysts love are Verve Therapeutics , CRISPR Therapeutics , Beam Therapeutics and Twist Bioscience.

☆ China is still racing to develop its own mRNA jabs. But they won't use foreign vaccines to fight COVID because of 'national pride,' says South Korea's top vaccine maker.
▼ + stars: | 2023-01-10 | by ( Huileng Tan | ) www.businessinsider.com time to read: +4 min

It hasn't yet approved any mRNA vaccines. But SK Bioscience says China is unlikely to source foreign COVID-19 vaccines, due to "national pride." SK Bioscience has developed its own COVID-19 vaccine, which is now being used in South Korea. "China has administered 3.4 billion doses of COVID vaccines for its people, covering over 90% of its population," said Liu. Even so, Chinese drugmakers are racing to produce mRNA vaccines against COVID-19.

☆ This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year
▼ + stars: | 2023-01-03 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +5 min

Emalex Bioscience is developing a new treatment for Tourette Syndrome. Tourette Syndrome currently has no cure and few treatment options. That's how in 2018 he came to found Emalex Biosciences, a pharmaceutical startup, to test a new drug for Tourette Syndrome. Emalex's drug works in a different way than other Tourette treatmentsIn spite of a tough market for biotech startups, Emalex has managed to raise $250 million from investors in November to develop its Tourette Syndrome drug candidate, called ecopipam. Many of the current approved therapies for Tourette Syndrome target D1 dopamine receptors in the brain.

Rapid tests have always been second to polymerase chain reaction, or PCR, assays when it comes to accuracy. Home-test kits have expiration datesAt-home COVID-19 test kits are one of the more convenient inventions to come out of the pandemic. Over-the-counter test kits typically have a sticker on the box indicating an expiration date and manufacturing date. One study found that false positives showed up when unexpected substances were directly applied to test kits. That is if you use the rapid test correctly and wait at least three-to-five days since a COVID-19 exposure to swab yourself.

☆ Novozymes is set to merge with Chr. Hansen as part of a historic deal
▼ + stars: | 2022-12-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovozymes is set to merge with Chr. Hansen as part of a historic dealEster Baiget, CEO of Novozymes, discusses the planned merger of bioscience firms Novozymes and Chr.

☆ Bioscience firms Novozymes and Chr. Hansen to merge in biggest-ever Danish deal
▼ + stars: | 2022-12-12 | by ( Elliot Smith | ) www.cnbc.com time to read: +1 min

Biotechnology firms Novozymes and Chr. Hansen agreed to combine in what will be the biggest-ever merger between two Danish companies. The new biosolutions group will have annual revenues of approximately 3.5 billion euros ($3.7 billion), the companies said. "Novozymes and Chr. Combining the two companies will create a global leader in biosolutions," Novo Holdings Chairman Lars Rebien Sørensen said.

And Wagner’s beloved fireflies – like so many insects worldwide – have largely vanished in what scientists are calling the global Insect Apocalypse. “Insects are the food that make all the birds and make all the fish,” said Wagner, who works at the University of Connecticut. Humans, too, see some 2,000 species of insects as food. “We’d see yields dropping of all of these crops.”And in nature, about 80% of wild plants rely on insects for pollination. WINNERS AND LOSERSWhile the situation is bleak for insects at large, a few types of insects are thriving.

☆ His Dodge Viper Is an Apex Predator on the Road
▼ + stars: | 2022-12-03 | by ( A.J. Baime | Photographs Eric Wagner For The Wall Street Journal | ) www.wsj.com time to read: 1 min

Emerson Moser , 46, of Cincinnati, general counsel for Meridian Bioscience, on his 2010 Dodge Viper ACR, as told to A.J. My dad was a General Motors engineer, and we spent a lot of time going to racetracks and car shows. When I was in college at Purdue in the 1990s, I was walking across campus one day when I saw a Dodge Viper on display in the Engineering Mall. I thought: This is the coolest, most exotic American car I have ever seen. It had a V-10 engine partially developed by Lamborghini.

☆ Trapview: Can an AI-powered insect trap solve a $220 billion pest problem?
▼ + stars: | 2022-11-24 | by ( Tom Page | ) edition.cnn.com time to read: +4 min

London CNN Business —Pests destroy up to 40% of the world’s crops each year, causing $220 billion in economic losses, according to the UN Food and Agriculture Organization (FAO). Trapview is harnessing the power of AI to help tackle the problem. Targeted interventionsThe automated devices have been used to monitor grapes, tomatoes, olives, tree fruits, and, pictured here, brassicas. Štefančič says that Trapview can significantly reduce the use of chemical sprays and the need for farmers to visit their fields. Trapview says it has sold over 7,500 devices in more than 50 countries since it launched in 2012.

☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
▼ + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.

☆ This biotech startup helps scientists design proteins using AI. Check out the 16-slide deck Cradle used to raise $5.4 million in seed funding.
▼ + stars: | 2022-11-17 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +3 min

Biotech startup Cradle just raised $5.4 million from Index Ventures and Kindred Capital. Check out the 16-slide deck Cradle used to raise the fresh funds. Inside that factory are proteins, which behave like machines," said cofounder Stef van Grieken. Amid a shaky economic downturn, van Grieken found that having a strong founding team — including Uber's first employee and a host of experienced biologists — helped with the fundraise. Investor appetite for generative AI and biotech has also remained stable, which was a boon, van Grieken added.

☆ Palm oil is in almost everything, and it's devastating rainforests. This Bill Gates-backed company used microbes to create an alternative
▼ + stars: | 2022-11-03 | by ( Catherine Clifford | In Catclifford | ) www.cnbc.com time to read: +11 min

Palm oil grows best in the regions right around the equator, so palm oil producers chop down rainforest and clear that felled vegetation by burning it, making it a prime target of conservation organizations like the Rainforest Rescue and the World Wildlife Fund. Palm oil trees grow at the Cikasungka palm oil plantation, operated by PT Perkebunan Nusantara VIII, in Bogor Regency in West Java, Indonesia, on Monday, June 20, 2022. To make its palm oil alternative, C16 Biosciences uses a wild yeast microbe that makes a functional equivalent to palm oil with a kind of fermentation process. Photo courtesy: Cat Clifford, CNBCChemically, the palm oil that C16 Biosciences makes is not identical to the palm oil that is grown in industrial agriculture farms. However, "it contains the same fatty acids, which are the molecular fingerprints of fats and oils, that palm oil does," Heller told CNBC.

☆ Three dead, including gunman, after shooting at St. Louis high school, officials say
▼ + stars: | 2022-10-24 | by ( Mirna Alsharif | Mirna Alsharif Is A Breaking News Reporter For Nbc News. | ) www.nbcnews.com time to read: +2 min

Three people are dead, including the gunman, after a shooting at a St. Louis high school Monday morning sent multiple people to hospitals, police said. Students were evacuated, and parents were directed to Gateway STEM High School to reunite with their children. People gather outside after a shooting at Central Visual and Performing Arts high school in St. Louis, on Monday, Oct. 24, 2022. He was pronounced dead a short time later, after exchanging gunfire with police, the St. Louis Metropolitan Police Department said during an afternoon news conference. Emergency personnel at the scene of a school shooting in St. Louis, Mo.

☆ Has the Phoenix Valley real estate market hit its pandemic ceiling? 7 industry experts debate if Phoenix's lofty home valuations are justified — or if there's a housing correction on the horizon for t
▼ + stars: | 2022-07-07 | by ( Lisa Kailai Han | ) www.businessinsider.com time to read: +15 min

Besides an overwhelming investor appetite, the surge in the Sunbelt's real estate prices can also be attributed to an influx of enthusiastic remote workers with deep pockets. "The Phoenix market was largely a COVID-19 pandemic market until about last summer," independent real estate market analyst John Wake told Insider, explaining that it was mainly owner-occupants driving the market. "In 2007, before the great recession, over 50% of our workforce was in real estate, construction, retail, and hospitality. Besides its investments into the biosciences and healthcare industry, Phoenix also has a stake in another global sector — semiconductor chip manufacturing. Eventually, Rounds forecasts a price correction of at least 25% for the Phoenix housing market.

☆ Условия въезда в Болгарию для молдавских туристов – Цензура МД
▼ + stars: | 2021-05-20 | by ( ) cenzura.md time to read: +1 min

Общество Условия въезда в Болгарию для молдавских туристовВ ситуации, когда из-за пандемии большинство стран ограничивают въезд для иностранцев, граждане Молдовы имеют возможность для отдыха на морских курортах в Болгарии. Тем не менее, и для въезда в Болгарию необходимо предъявление ряда документов. Граждане Республики Молдова могут въезжать на территорию Республики Болгария при представлении одного из следующих документов:1. Отрицательный результат теста на антигены, проведенного за 48 часов до въезда в Болгарию. При этом, необходимо учитывать, что проблем в организованных группах туристов гораздо меньше, чем в индивидуальных поездках в туристических целях в Болгарию.

Locations: Болгария, Молдова, Республика Молдова, Республика Болгария, Румыния

☆ Как гражданам Молдовы отдохнуть этим летом в Болгарии. Условия
▼ + stars: | 2021-05-20 | by ( Mld Media Srl | Степанов Георгий | ) noi.md time to read: +2 min

Следует отметить, что для поездок в Болгарию гражданам Молдовы с биометрическими паспортами виза не нужна. Кроме того, в связи с продолжающейся пандемией COVID-19 граждане Республики Молдова могут въезжать на территорию Республики Болгария при представлении одного из следующих документов:1. При транзите через территорию Румынии гражданам Республики Молдова рекомендуется иметь при себе медицинскую страховку, а также документ, подтверждающий наличие бронирования в Болгарии. Если румынские пограничные власти откажут в разрешении гражданину Молдовы въехать на свою территорию, необходимо запросить официальный документ об отказе. Для въезда в Болгарию наземным транспортом доступны следующие таможенные пункты: ГКПП „Дуранкулак“; ГКПП „Русе“; ГКПП „Аерогара Бургас“; ГКПП „Аерогара Варна“; ГКПП „Аерогара Пловдив“; ГКПП „Аерогара София“ (Терминал 1 и Терминал 2); ГКПП „Пристанище Бургас“; ГКПП „Пристанище Варна“; ГКПП „Видин“; ГКПП „Връшка чука“; ГКПП „Гюешево“; ГКПП „Илинден“; ГКПП „Калотина“; ГКПП „Капитан Андреево“; ГКПП „Капитан Петко войвода“; ГКПП „Кулата“; ГКПП „Лесово“; ГКПП „Маказа“; ГКПП „Малко Търново“; ГКПП „Оряхово“ и ГКПП „Сомовит-Никопол“.

Persons: Аерогара Варна, Капитан Андреево Organizations: ГКПП „Дуранкулак“ ГКПП „Русе“ ГКПП „Аерогара Бургас, ГКПП, Терминал, ГКПП „Видин“ ГКПП „Връшка чука“ ГКПП „Гюешево“ ГКПП „Илинден“ ГКПП „Калотина“ ГКПП „, ГКПП „Кулата“ ГКПП „Лесово“ ГКПП „Маказа“ ГКПП „Малко Търново“ ГКПП „Оряхово Locations: Молдова, Болгария, Республика Молдова, Республика Болгария, Румыния

☆ Moldova urmează să inițieze procedura de achiziție a 400.000 de doze de vaccin CoronaVac, produs de SINOVAC
▼ + stars: | 2021-04-09 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Astăzi, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China, singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin.Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare.Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Acesta se păstrează la temperatura de 2-8 grade Celsius.Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Invitații au fost transmise producătorilor de vaccin împotriva COVID-19: Pfizer Inc, Moderna Inc, Johnson & Johnson Inc, AstraZeneca PLC, Sinopharm Group Co. Ltd, Russian Direct Investment Fund, Serum Institute of India, AstraZeneca/SK Bioscience Co.Ltd, Sinovac Biotech Ltd. și CanSino Biologics Inc.Menționăm că, CAPCS continuă negocierile directe, exclusiv cu producătorii de vaccin împotriva COVID-19, pentru asigurarea țării cu doze de vaccin în contextul implementării Planului național de imunizare împotriva COVID-19.

Persons: Johnson Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ CAPCS urmează să inițieze procedura de achiziție a 400 000 de doze de vaccin CoronaVac, produs de SINOVAC BIOTECH LIMITED din China
▼ + stars: | 2021-04-09 | by ( Diana Severin | ) www.zdg.md time to read: +4 min

Ministerul Sănătății, Muncii și Protecției Sociale (MSMPS) anunță că vineri, 9 aprilie, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China. Potrivit MSMPS, acesta este singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin. Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Licitația pentru procurarea dozelor de vaccin anti-COVID pentru utilizarea în cadrul planului național de imunizare COVID-19 a eșuat.

Persons: Johnson, MSMPS, CAPCS Organizations: Ministerul Sănătății, Muncii, Protecției Sociale, Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience, Inc, Agenția Europeană, Organizației Mondiale a Sănătății Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd, Moldova

☆ В Молдове хотят закупить 400 000 доз вакцины CoronaVac производства SINOVAC
▼ + stars: | 2021-04-09 | by ( ) nokta.md time to read: +1 min

Руководящий комитет по координации иммунизации COVID-19 собрался сегодня, чтобы изучить предложение китайского производителя вакцины против COVID-19, SINOVAC BIOTECH LIMITED. По информации Минздрава, это единственный производитель вакцин, ответивший на запросы Центра централизованных закупок в области здравоохранения (CAPCS), производителей вакцин. Таким образом, после анализа предложения, члены Комитета приняли решение напрямую заключить контракт на 400 000 доз вакцины CoronaVac, производимой SINOVAC, после установления всех условий контракта. На сегодняшний день CAPCS запустила две процедуры закупок: переговоры без предварительной публикации уведомления о контракте и открытый тендер, в рамках которого не было подано никаких предложений. Приглашения были отправлены производителям вакцины против COVID-19: Pfizer Inc., Moderna Inc., Johnson & Johnson Inc., AstraZeneca PLC, Sinopharm Group Co. Ltd, Российский фонд прямых инвестиций, Индийский институт сыворотки, AstraZeneca / SK Bioscience Co.Ltd, Sinovac Biotech Ltd. и CanSino Biologics Inc.CAPCS продолжает прямые переговоры с производителями вакцины против COVID-19 о предоставлении стране доз вакцины в контексте реализации Национального плана иммунизации против COVID-19.

Persons: Johnson, CAPCS Organizations: Pfizer Inc, Moderna Inc, Johnson Inc, AstraZeneca PLC, Sinopharm, Ltd, AstraZeneca, SK Bioscience Co.Ltd, Sinovac Biotech, CanSino Biologics, Руководящий комитет, Минздрав, Центр централизованных закупок, Комитет, Российский фонд прямых инвестиций, Индийский институт сыворотки Locations: COVID, Украина

La ședința de astăzi a Comitetului de coordonare a imunizării împotriva COVID-19 a fost examinată oferta producătorului de vaccin împotriva COVID-19 Sinovac Biotech din China, în urma căreia s-a decis contractarea directă a 400 000 de doze de vaccin CoronaVac. Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Acesta se păstrează la temperatura de 2-8 grade Celsius. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă.

Persons: Johnson, Inc Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ CAPCS planifică să procure 400 000 de doze de vaccin chinezesc: „Este singurul producător care a răspuns la solicitare”
▼ + stars: | 2021-04-09 | by ( ) www.jurnal.md time to read: +1 min

Sursa foto: Jurnal.mdCAPCS planifică să procure 400 000 de doze de vaccin chinezesc: „Este singurul producător care a răspuns la solicitare”Astăzi, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China, singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin. Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare. Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă.

Persons: Johnson Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience, Inc Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ Китай предоставит Молдове 400 тысяч доз вакцины Sinovac Biotech
▼ + stars: | 2021-04-09 | by ( ) ru.diez.md time to read: 1 min

На сегодняшнем заседании Руководящего комитета по иммунизации COVID-19 было рассмотрено предложение производителя вакцины COVID-19 Sinovac Biotech из Китая, после чего было решено напрямую заключить контракт на 400 000 доз вакцины CoronaVac. Она вводится внутримышечно в 2 приема с интервалом 28 дней. Вакцину нужно хранить при температуре 2-8 градусов по Цельсию. На сегодняшний день CAPCS запустила две процедуры закупок: переговоры без предварительной публикации уведомления о контракте и открытый тендер. Приглашения разосланы следующим производителям вакцины против COVID-19: Pfizer Inc, Moderna Inc, Johnson & Johnson Inc, AstraZeneca PLC, Sinopharm Group Co. Ltd, Russian Direct Investment Fund, Serum Institute of India, AstraZeneca/SK Bioscience Co.Ltd, Sinovac Biotech Ltd. и CanSino Biologics Inc.

Organizations: Biotech, Pfizer Inc, Moderna Inc, Johnson, Johnson Inc, AstraZeneca PLC, Sinopharm, Russian Direct Investment Fund, Serum Institute of India, AstraZeneca, SK Bioscience Co.Ltd, Sinovac Biotech, CanSino Biologics Inc, Руководящий комитет Locations: Китай, Украина

☆ Autoritățile planifică să procure 400 000 de doze de vaccin chinezesc: „Este unicul producător care a răspuns la solicitare”
▼ + stars: | 2021-04-09 | by ( ) www.jurnal.md time to read: +1 min

Sursa foto: Jurnal.mdAutoritățile planifică să procure 400 000 de doze de vaccin chinezesc: „Este unicul producător care a răspuns la solicitare”Astăzi, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China, singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin. Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare. Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă.

Persons: Johnson Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience, Inc Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ Молдова закупит 400 тысяч доз китайской вакцины – Цензура МД
▼ + stars: | 2021-04-09 | by ( ) cenzura.md time to read: +1 min

Общество Молдова закупит 400 тысяч доз китайской вакциныМолдова закупит 400 000 доз вакцины CoronoVac, производимой китайской компанией Sinovac. Решение приняли 9 апреля члены Координационного совета по иммунизации против COVID-19. Это единственный производитель вакцин, который ответил на запросы Центра централизованных государственных закупок (CAPCS) в здравоохранении, – отмечается в пресс-релизе Минздрава. На сегодняшний день CAPCS запустила две процедуры закупок: переговоры без предварительной публикации уведомления о контракте и открытый тендер. Приглашения были отправлены производителям вакцины против COVID-19: Pfizer Inc., Moderna Inc., Johnson & Johnson Inc., AstraZeneca PLC, Sinopharm Group Co. Ltd, Российский фонд прямых инвестиций, Индийский институт сыворотки, AstraZeneca / SK Bioscience Co.Ltd, Sinovac Biotech Ltd. и CanSino Biologics Inc.

Persons: Johnson Organizations: Pfizer Inc, Moderna Inc, Johnson Inc, AstraZeneca PLC, Sinopharm, Ltd, AstraZeneca, SK Bioscience Co.Ltd, Sinovac Biotech, CanSino Biologics Inc, вакциныМолдова, Координационный совет, Центр централизованных государственных закупок (), Минздрав, Российский фонд прямых инвестиций, Индийский институт сыворотки Locations: Sinovac, Общество Молдова, Украина

Search resuls for: "BioScience"

25 mentions found